Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
Ionis' inhaled antisense medicine demonstrates potential as a novel treatment for cystic fibrosis
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis.
Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer.
Insmed Receives Positive CHMP Opinion for ARIKAYCE Liposomal 590 mg Nebuliser Dispersion for the Treatment of NTM Lung Infections Caused by MAC in Non-CF Patients with Limited Treatment Options
New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease
